AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
AZN•
AZN•A federal judge ruled that Alexion Pharmaceuticals, AstraZeneca’s unit, was immune from an antitrust lawsuit alleging it used patents to maintain a Soliris monopoly. The health plan’s complaint estimated overpayments at more than $2 billion.
A federal judge in Massachusetts ruled that Alexion Pharmaceuticals was immune from claims brought by health plan EmblemHealth over alleged misuse of patents for Soliris. The lawsuit accused Alexion of maintaining a monopoly on the blood-disease drug.
EmblemHealth alleged that Alexion wrongly obtained new patents to block Soliris biosimilars for four years after its earlier patents expired, and used the patents to delay competitors’ products until March 2025 at the earliest. The complaint said the alleged conduct caused more than $2 billion in overpayments.
AstraZeneca earned more than $1.8 billion from Soliris sales last year, according to a company report. The judge rejected EmblemHealth’s argument that immunity did not apply because Alexion allegedly brought sham litigation to enforce the patents.